Navigation Links
Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
Date:11/20/2008

ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) announced today the global release of MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA are expected to allow researchers to successfully take the next step in their RNAi research with the highest purity and quality siRNA required for RNAi research in animal models. These siRNA are believed to be well suited to target validation and pre-clinical siRNA testing. Intermediate and large synthesis scales and a wide variety of modifications are also available.

"Increasingly, RNAi researchers are utilizing animal models to confirm findings from cell culture based assays or to explore the use of siRNA as a potential therapeutic agent," said Tim Fleming, Director of Global Commercial Marketing at Sigma-Aldrich. "Our goal is to provide an siRNA that is capable of facilitating in vivo siRNA research, with the purity levels required for direct delivery or to be used as an essential part of an overall in vivo formulation strategy."

MISSION(R) In VIVO QUALITY siRNA are processed specifically for in vivo usage. This purification process includes RP-HPLC to ensure a high percentage of full-length product (>94%), dialysis on the annealed product to remove excess salts, 22 micrometer sterile filtration, and finally testing to ensure no endotoxins are present.

In addition, iScale Oligos(TM) synthesis scales can give customers the large quantities of siRNA required for in vivo usage with amounts up to 100mg. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA are available with many of the common modifications used to for tracking or stability, such as FAM, Cy5(TM), and Cy3(TM).

"Sigma-Aldrich's MISSION(R) In VIVO QUALITY siRNAs are used exclusively at BIOO Scientific(TM) for all of our internal in vivo formulation development programs," said Lance Ford, Vice President of Research and Development at BIOO Scientific(TM) Corporation. "Most recently, we have used these siRNAs to with great success to demonstrate the utility of our new in vivo formulation, MaxSuppressor(TM) In Vivo RNA-LANCEr II (catalog #3410-01), in mouse models. BIOO Scientific(TM) Corporation recommends these siRNAs to our all of our customers as they are exceptional siRNAs, offered at a competitive price, with rapid turnaround times and supported by Sigma-Aldrich's professional service."

For more information on the MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, please visit sigma-aldrich.com/invivosirna .

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning website at http://www.sigma-aldrich.com.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research
3. Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
4. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
5. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
6. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
7. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
8. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
9. Sigma-Aldrich to Present at the UBS 2008 Global Life Sciences Conference on September 24, 2008
10. Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
11. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... BEACH, Florida , February 11, 2016 /PRNewswire/ ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), ... diagnostics, announced today that its Thermomedics subsidiary, which ... progress on its growth plan in January 2016, ... products distributors, increasing sequential monthly sales growth, and ...
(Date:2/10/2016)... , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: ... pleased to announce that Mitsui & Co. Ltd., its ... succinic acid plant, is investing an additional CDN$25 million ... increasing its stake from 30% to 40%.  Mitsui will ... bio-succinic acid produced in Sarnia , ...
(Date:2/10/2016)... , ... February 10, 2016 ... ... today announced that it has joined the Human Vaccines Project, a public-private ... diseases and cancer. , The Human Vaccines Project brings together leading ...
(Date:2/10/2016)... Springfield, MO (PRWEB) , ... February 10, 2016 ... ... company, will attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter ... of ISPE is expecting to fill more than 100 tables for its annual ...
Breaking Biology Technology:
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... MedNet,s significant achievements are the result of the company,s ... iMedNet eClinical , it,s comprehensive, easy-to-use and ... --> Key MedNet growth achievements in ...
(Date:1/18/2016)... Jan. 18, 2016  Extenua Inc., a pioneering ... the use and access of ubiquitous on-premise and ... with American Cyber.  ... leading transformational C4ISR and Cyber initiatives in support ... latest proven technology solutions," said Steve Visconti ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
Breaking Biology News(10 mins):